Javier Molina-Cerrillo
Dr Javier Molina-Cerrillo, MD, PhD is an expert in Oncology at Hospital Universitario Ramón y Cajal (Spain). As of October 2026, ScienceLeadR ranks Javier Molina-Cerrillo in the top 1% of experts worldwide for Kidney Neoplasms and Carcinoma. Javier Molina-Cerrillo has authored 186 publications, the most recent in 2026, and is an investigator in 15 clinical trials, 10 of them ongoing. SLR score: 802 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Urology - Immunology - Pharmacy
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2015 - 2026
Number : 186
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| CABOPRE: Evaluating Perioperative Cabozantinib's Efficacy and Biomarkers for Cytoreductive Nephrectomy in Advanced Renal Cell Carcinoma. PMID 42882910 — cells, neoplasms, nephrectomy, carcinoma, renal cell, biomarkers, therapeutics | Cancers (Basel) | 2026 | 0 |
| Real-World HRR Testing Pathways and Patterns of Detected Alterations in Prostate Cancer From the Multinational ARON-3 Study. PMID 42862920 — research design, genes, genomics, poly(adp-ribose) polymerases, neoplasms, prostate, poly adenosine diphosphate ribose, biomarkers, recombinational dna repair, prostatic neoplasms, precision medicine | Prostate | 2026 | 0 |
| Global Disparities in the Availability and Reimbursement of Systemic Therapies for Renal Cell Carcinoma: Results of the International ARON-AID Survey. PMID 42836687 — cells, radiation oncologists, oncologists, pharmaceutical preparations, neoplasms, income, carcinoma, renal cell, therapeutics | Oncologist | 2026 | 0 |
| Prognostic value of PD-L1 in patients with metastatic renal cell carcinoma (mRCC) treated with antiangiogenic first line drugs (PROANG-SOGUG study). PMID 42803874 — cells, pharmaceutical preparations, neoplasms, carcinoma, renal cell, therapeutics | Clin Transl Oncol | 2026 | 0 |
| Theranostics in the management of prostate cancer: from concept to clinical practice. PMID 42770599 — poly(adp-ribose) polymerases, neoplasms, prostate, poly adenosine diphosphate ribose, prostatic neoplasms, pharmacology, clinical, therapeutics, molecular imaging | Expert Rev Clin Pharmacol | 2026 | 0 |
Clinical Studies 15
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
10 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK 6482 033) 2024-517136-21-00 — cells, neoplasms, kidney, carcinoma, renal cell, respect, kidney neoplasms, therapeutics, carcinoma | Phase 3 | Recruiting | 2025 |
| Multicenter open label single arm phase II study to assess the efficay and safety of enfortumab vedotin (EV) as a single agent in patients with advanced Neuroendocrine Carcinomas (NEC) 2024-515511-21-00 — lung, safety, drug therapy, carcinoma, neuroendocrine, chemotherapy, carcinoma | Phase 2 | Recruiting | 2025 |
| Lu177 Dotatate every 16 weeks to reduce adverse events in patients with midgut neuroendocrine tumors 2024-517921-14-00 — neoplasms, drug-related side effects and adverse reactions, neuroendocrine tumors | Phase 1/Phase 2 | Recruiting | 2025 |
| Study to evaluate the efficacy and safety of 177Lu Lu DOTA TATE in patients with Grade 1 and Grade 2 advanced GEP NET (NETTER 3) 2024-518325-15-00 — safety, neoplasms, multiple chronic conditions, neuroendocrine tumors, cost of illness | Phase 3 | Recruiting | 2025 |
| Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus NCT05918302 — radiotherapy, lung, somatostatin, safety, thymus neoplasms, neoplasms, everolimus, neuroendocrine tumors, receptors, somatostatin, patient reported outcome measures, thymus gland, therapeutics, receptors, peptide, octreotide | Phase 3 | Recruiting | 2023 |
LeadR Networks
Main global connection map